This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Myeloid leukemia cell differentiation protein (Mcl-1) dependency as a marker for chemotherapy sensitivity	<p>Studies in cell culture suggest that leukemia cells that depend on Mcl-1 for survival could be more sensitive to chemotherapy than BCL2-dependent cells. Mcl-1-dependent mouse leukemia cell lines were generated along with a complementary set of B-cell lymphoma 2 (BCL-2; BCL2)-dependent cells that had identical morphology, cell-surface phenotype and clinical behavior. In dose-response studies, the three Mcl-1-dependent cell lines had greater sensitivity to eight chemotherapeutic agents than their complementary BCL2-dependent cell lines. Next steps include carrying out proof-of-principle clinical studies.</p> <p>SciBX 2(42); doi:10.1038/scibx.2009.1587 Published online Oct. 29, 2009</p>	<p>Patent application filed covering profiling technology used to distinguish between Mcl-1- and BCL2-dependent cancers; profiling technology licensed to Eutropics Pharmaceuticals Inc.; profiling technology available for licensing from Eutropics; cancer models available for licensing from the Dana-Farber Cancer Institute Office of Research Technology Ventures</p>	<p>Brunelle, J.K. <i>et al. J. Cell Biol.</i>; published online Oct. 26, 2009; doi:10.1083/jcb.200904049 Contact: Anthony Letai, Dana-Farber Cancer Institute, Boston, Mass. e-mail: Anthony_Letai@dfci.harvard.edu</p>